Contains fulltext : 50982.pdf (publisher's version ) (Closed access)Originally, itraconazole for parenteral administration was licensed in a 40% hydroxypropyl-beta-cyclodextrin (HPBCD) solution for intravenous administration. A novel formulation, the NanoCrystal formulation (NCF), was prepared. NCF consists of drug particles of approximately 200 to 300 nm. The pharmacokinetics of itraconazole and its hydroxy metabolite in healthy subjects were evaluated after single and multiple doses of itraconazole as NCF. In the single-ascending-dose (SAD) study, itraconazole doses were planned to range from 50 to 500 mg, while in the multiple-ascending-dose (MAD) study, itraconazole doses of 100, 200, and 300 mg as NCF were studied, as...
The pharmacokinetics and safety of an intravenous hydroxypropyl-beta-cyclodextrin solution of itraco...
Contains fulltext : 70639.pdf (publisher's version ) (Closed access)Voriconazole i...
We explored concentration-toxicity relationships for itraco-nazole among 216 patients. Logistic regr...
Originally, itraconazole for parenteral administration was licensed in a 40% hydroxypropyl-beta-cycl...
Pharmacokinetics of itraconazole and hydroxy-itraconazole in healthy subjects after single and multi...
Itraconazole is an orally active antifungal agent that has complex and highly variable absorption ki...
Itraconazole is an orally active antifungal agent that has complex and highly variable absorption ki...
Objective: The objective of the study was to characterise the population pharmacokinetic properties ...
Itraconazole is a triazole antifungal used in the treatment of allergic bronchopulmonary aspergillos...
The safety, tolerability, and pharmacokinetics of an oral solution of itraconazole and its active me...
Objectives: The aim of the study was to characterise the population pharmacokinetics (popPK) propert...
Background and Objective: Super bioavailable itraconazole is a newer formulation of itraconazole, wh...
Objectives : Solid dispersion formulations have attracted attention to improve solubility and bioava...
The pharmacokinetics of itraconazole formulated in a hydroxypropyl-b-cyclodextrin oral solution was ...
The pharmacokinetics and safety of an intravenous hydroxypropyl-beta -cyclodextrin solution of itrac...
The pharmacokinetics and safety of an intravenous hydroxypropyl-beta-cyclodextrin solution of itraco...
Contains fulltext : 70639.pdf (publisher's version ) (Closed access)Voriconazole i...
We explored concentration-toxicity relationships for itraco-nazole among 216 patients. Logistic regr...
Originally, itraconazole for parenteral administration was licensed in a 40% hydroxypropyl-beta-cycl...
Pharmacokinetics of itraconazole and hydroxy-itraconazole in healthy subjects after single and multi...
Itraconazole is an orally active antifungal agent that has complex and highly variable absorption ki...
Itraconazole is an orally active antifungal agent that has complex and highly variable absorption ki...
Objective: The objective of the study was to characterise the population pharmacokinetic properties ...
Itraconazole is a triazole antifungal used in the treatment of allergic bronchopulmonary aspergillos...
The safety, tolerability, and pharmacokinetics of an oral solution of itraconazole and its active me...
Objectives: The aim of the study was to characterise the population pharmacokinetics (popPK) propert...
Background and Objective: Super bioavailable itraconazole is a newer formulation of itraconazole, wh...
Objectives : Solid dispersion formulations have attracted attention to improve solubility and bioava...
The pharmacokinetics of itraconazole formulated in a hydroxypropyl-b-cyclodextrin oral solution was ...
The pharmacokinetics and safety of an intravenous hydroxypropyl-beta -cyclodextrin solution of itrac...
The pharmacokinetics and safety of an intravenous hydroxypropyl-beta-cyclodextrin solution of itraco...
Contains fulltext : 70639.pdf (publisher's version ) (Closed access)Voriconazole i...
We explored concentration-toxicity relationships for itraco-nazole among 216 patients. Logistic regr...